Perioperative medicine & outcomes
Withholding or continuing glucose-lowering drugs for elective surgery in patients with type 2 diabetes mellitus: a secondary analysis of the MOPED international, prospective, observational study
Primary result · DAH-30 among metformin usersResult — go to the resultDifference 0.47 days 95% CI 0.01–0.93Authors' conclusion
Continuing metformin during surgery among patients with type 2 diabetes mellitus was associated with marginally shorter DAH-30, but the sample size for participants receiving SGLT2i and GLP-1 RA therapy precluded any meaningful estimates.
Study context
- Population
- Patients with type 2 DM undergoing elective surgery in 21 European countries
- Participants
- 5,767 patients · 89 centres
- Comparison
- Continuing vs withholding glucose-lowering drugs for elective surgery
- Continued metforminn = 421
- Not taken metforminn = 3,202reference
- Primary endpoint
- Days alive at home and out of hospital (DAH-30)
- Follow-up
- 30 days
Methodological detailsinternational, multicentre
- International
- Multicentre
Primary result
DAH-30 among metformin users
Difference
0.47 days
95% CI 0.01–0.93
P = 0.044
By group
Continued metformin vs Not taken metformin
difference 0.47 days (95% CI 0.01–0.93); P = 0.044
As reported in the abstract
Further findings
DAH-30, stopping/continuing SGLT2i (n=836) or GLP-1 RA (n=304) · 30 days
- No association found for SGLT2i or GLP-1 RA with DAH-30
Original publication
Withholding or continuing glucose-lowering drugs for elective surgery in patients with type 2 diabetes mellitus: a secondary analysis of the MOPED international, prospective, observational study. Br J Anaesth. Published 26 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →